(Yicai Global) Sept. 21 -- Beijing Infervision acquired CNY120 million (USD18.1 million) in B-round financing, which is currently the largest single financing in international artificial intelligence (AI) medical imaging industry, the company said today.
This round of financing was jointly backed by Qiming Venture Partners, Genesis Capital and Sequoia Capital China. The company received CNY50 million in A-round financing last January, 36Kr reported.
Beijing Infervision mainly focuses on the AI-assisted medical imaging diagnosis of lung and heart diseases. In May, Beijing Infervision officially released the "Infervision technology – artificial intelligence precision healthcare platform," to introduce intelligent X-ray screening product and intelligent CT screening product for the first time, which have been put into trial in several hospitals in Shanghai. The research and development (R & D) of its intelligent Magnetic Resonance Imaging (MRI) assisted diagnostic product and other new products will also be finalized.
After this round of financing, Infervision will accelerate the commercialization of the AI technology in the medical industry, extend it to clinical applications, and expand the international market, it said. In the future, Infervision products will cover AI-assisted screening for brain, fracture, heart, breast and abdominal areas.